Because CNAT has already shown to reduce fibrosis. In the POLT study from F3 through F5 fibrosis population it achieved a 95% response rate. Even though the title read as a fail, in essence the trial was a success. If you were to also take out the 3 placebo patients with F6 level fibrosis at 100% the trial would have met on the primary endpoint.